ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio Inc. shares will react Monday to news of a fresh bladder-cancer supply agreement. The company said Saturday it now has exclusive U.S. rights to develop, import and sell the Tokyo-172 BCG strain from Japan BCG Laboratory.

17 May 2026

ImmunityBio stock jumps before the open after FDA outlines next step for ANKTIVA filing

ImmunityBio shares rose about 27% to $7 in premarket trading on Tuesday, with about 4.1 million shares changing hands, after the company said it had made progress with the U.S. Food and Drug Administration on a path to revive a label-expansion push for its bladder cancer treatment ANKTIVA.

20 January 2026

Biotechnology·NASDAQ:IBRX.O·Stock Market

ImmunityBio stock jumps before the open after FDA outlines next step for ANKTIVA filing

TechStock² Updates

Marvell Shares Drop 10.3%, Wiping Out $22 Billion Amid Google Revenue Delay to 2029

Ambev Shares Slide 0.7%, 30 Million Shares Test 31.6% Margin Rebound

Coeur Mining Stock Falls 4.9%, Erasing $1.1 Billion as Metals Slide

B2Gold Reports Masbate Fatality After Stock Falls 2.9%; Production Continues

IREN Shares Drop 12.5% With $4 Billion AI Expansion Pushing Up Against $6.4 Billion Financing Hurdle

NVIDIA Sheds 4.6% and Loses $252 Billion in Value as Margin Concerns Emerge Over Memory Prices

SpaceX Shares Edge Up 0.5% with $1.86 Trillion Value as Quarterly Capex Hits $18.4 Billion

Intel Shares Drop 2.9%, Remain 5.8% Under $95 Offering as Company Delivers 25% Revenue Gain

PG&E Shares Drop 7.5%, Wiping Out $3 Billion After Delay to California Wildfire Shield

DraftKings Faces $67.6 Million Loss on $13.1 Billion U.S. Open Betting Volume

Investment Disclaimer